Stockscreener 앱 받기
1.24
0.81%
0.01
시간 외 거래:
1.24
전일 마감가:
$1.23
열려 있는:
$1.23
하루 거래량:
1.29M
Relative Volume:
1.19
시가총액:
$76.20M
수익:
$5.03M
순이익/손실:
$-185.41M
주가수익비율:
-0.4013
EPS:
-3.09
순현금흐름:
$-139.79M
1주 성능:
-3.13%
1개월 성능:
-26.19%
6개월 성능:
-10.14%
1년 성능:
-90.68%
1일 변동 폭
$1.1901
$1.29
1주일 범위
$1.1901
$1.345
52주 변동 폭
$1.1001
$15.00
Pliant Therapeutics Inc Stock (PLRX) Company Profile
명칭
Pliant Therapeutics Inc
전화
650-481-6770
주소
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
PLRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.24 | 75.58M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 재개 | Cantor Fitzgerald | Neutral |
| 2025-03-04 | 다운그레이드 | Needham | Buy → Hold |
| 2025-03-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-02-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-05-18 | 개시 | Canaccord Genuity | Buy |
| 2023-04-13 | 개시 | Robert W. Baird | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-07 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Outperform |
| 2022-05-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-03 | 개시 | H.C. Wainwright | Buy |
| 2021-04-20 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Cowen | Outperform |
| 2020-06-29 | 개시 | Needham | Buy |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
모두보기
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Is Pliant Therapeutics Inc a good long term investmentHead and Shoulders Patterns & Superior Portfolio Investment - earlytimes.in
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre - Investing.com Nigeria
Pliant Therapeutics Announces Departure of Chief Medical Officer - TradingView
Pliant Therapeutics Inc (PLRX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Pliant Therapeutics shares rise after early cancer drug data impresses - MSN
Rishiroop Limited Recovery Likely Heres What Data ShowsVolume Analysis Techniques & Rapid Capital Portfolio - earlytimes.in
Pliant Therapeutics (PLRX) Stock Analysis Report | Financials & Insights - Benzinga
Pliant Therapeutics reports interim PLN-101095 Phase I trial data - Yahoo
Pliant’s PLN-101095 shows promising results in cancer trial By Investing.com - Investing.com Nigeria
Can Pliant Therapeutics Inc. stock sustain revenue growthJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - Newser
What hedge fund moves indicate for Pliant Therapeutics Inc. (9PT) stockJuly 2025 Review & Free Safe Capital Growth Stock Tips - Newser
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsJuly 2025 Snapshot & Risk Controlled Daily Trade Plans - Newser
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerBear Alert & Risk Controlled Daily Plans - Newser
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors - inkl
Pliant Therapeutics, Inc. (PLRX) -15.3% in Intraday Trading: Interim Data Announcement Fails to Support Price - Stocks Telegraph
Pliant Therapeutics stock jumps on promising cancer drug trial results By Investing.com - Investing.com South Africa
Pliant Therapeutics stock jumps on promising cancer drug trial results - Investing.com
Pliant Therapeutics, Inc. Announces Interim Data from Pln-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - marketscreener.com
Pliant’s PLN-101095 shows promising results in cancer trial - Investing.com
Pliant Therapeutics reveals promising early results for PLN-101095 - Traders Union
Pliant Therapeutics announces interim data from PLN-101095 - marketscreener.com
Pliant Therapeutics (Nasdaq: PLRX) reports interim PLN-101095 data with 1 CR, 3 PRs - Stock Titan
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Sahm
Is Pliant Therapeutics Inc. (9PT) stock considered safe havenTrade Volume Report & Community Consensus Stock Picks - Newser
Are Smart Investors Making the Right Decision? Pliant Therapeutics Inc (PLRX) - setenews.com
Will Pliant Therapeutics Inc. (9PT) stock profit from fiscal stimulusMarket Risk Summary & Verified Swing Trading Watchlist - Newser
Will Pliant Therapeutics Inc. stock attract more institutional investors - Newser
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - Investing News Network
Pliant Therapeutics Inc Stock Analysis and ForecastRSI Overbought/Oversold & Insights From Wall Street Professionals - earlytimes.in
What drives Pliant Therapeutics Inc stock priceCapital Gains Strategies & Access Advanced Stock Screening Tools - earlytimes.in
Wall Street analysts’ outlook for Pliant Therapeutics Inc (PLRX) - setenews.com
Total debt per share of Pliant Therapeutics, Inc. – SWB:9PT - TradingView
Pliant Therapeutics, Inc. (PLRX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why Pliant Therapeutics Inc. (9PT) stock benefits from AI revolutionWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
Why Pliant Therapeutics Inc. stock is in analyst buy zone2025 Price Targets & Low Drawdown Investment Strategies - newser.com
How rising interest rates impact Pliant Therapeutics Inc. stockJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Pliant Therapeutics Inc (PLRX) expanding its growth trajectory ahead - Setenews
Why global investors buy Pliant Therapeutics Inc. (9PT) stock2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
What high frequency data says about Pliant Therapeutics Inc.July 2025 News Drivers & Risk Adjusted Buy/Sell Alerts - newser.com
Pliant Therapeutics Inc (PLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pliant Therapeutics Inc 주식 (PLRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
0.36%
1.05%
자본화:
|
볼륨(24시간):